NCT00745030View on ClinicalTrials.gov

Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism

NATerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
REM Behavior DisorderParkinsonism
Interventions
DRUG

Rozerem

Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.

DRUG

Placebo

Placebo 8 mg tablets

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Northwestern University

OTHER